BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Adv Ther 2017;34:2452-65. [PMID: 29076108 DOI: 10.1007/s12325-017-0628-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Numakura K, Nakai Y, Kojima T, Osawa T, Narita S, Nakayama M, Kitamura H, Nishiyama H, Shinohara N. Overview of clinical management for older patients with renal cell carcinoma. Jpn J Clin Oncol 2022:hyac047. [PMID: 35397166 DOI: 10.1093/jjco/hyac047] [Reference Citation Analysis]
2 Wilson LE, Spees L, Pritchard J, Greiner MA, Scales CD Jr, Baggett CD, Kaye D, George DJ, Zhang T, Wheeler SB, Dinan MA. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States. Kidney Cancer 2021;5:115-27. [PMID: 34632169 DOI: 10.3233/KCA-210119] [Reference Citation Analysis]
3 Deng H, Huang Y, Hong Z, Yuan X, Cao Z, Wei Y, Zhang W. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis. BMC Cancer 2019;19:489. [PMID: 31122210 DOI: 10.1186/s12885-019-5704-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Manseck A, Manseck S, Körner C. [Concepts in geriatric uro-oncology]. Urologe A 2019;58:403-9. [PMID: 30859232 DOI: 10.1007/s00120-019-0892-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2020;126:1-10. [PMID: 31887537 DOI: 10.1016/j.ejca.2019.10.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
6 Dupuis HGA, Chebbi A, Surlemont L, Rigal O, Di Fiore F, Pfister C, Nouhaud FX. Efficacy and safety of anti-vascular endothelial growth factor therapies in older patients for first line treatment of metastatic renal cell carcinoma. Transl Androl Urol 2021;10:2418-26. [PMID: 34295728 DOI: 10.21037/tau-20-1481] [Reference Citation Analysis]
7 Chien CR, Geynisman DM, Kim B, Xu Y, Shih YT. Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review. Pharmacoeconomics 2019;37:301-31. [PMID: 30467701 DOI: 10.1007/s40273-018-0746-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Pierantoni F, Basso U, Maruzzo M, Lamberti E, Bimbatti D, Tierno G, Bergo E, Brunello A, Zagonel V. Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. J Geriatr Oncol 2021;12:290-7. [PMID: 32972885 DOI: 10.1016/j.jgo.2020.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Capri S, Porta C, Condorelli C, Premoli E, Khare A, Kalra M, Modi N, Ratto B. An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy. J Med Econ 2020;23:1579-87. [PMID: 33079593 DOI: 10.1080/13696998.2020.1839240] [Reference Citation Analysis]
10 Facchini G, Rossetti S, Berretta M, Cavaliere C, Scagliarini S, Vitale MG, Ciccarese C, Di Lorenzo G, Palesandro E, Conteduca V, Basso U, Naglieri E, Farnesi A, Aieta M, Borsellino N, La Torre L, Iovane G, Bonomi L, Gasparro D, Ricevuto E, De Tursi M, De Vivo R, Lo Re G, Grillone F, Marchetti P, De Vita F, Scavelli C, Sini C, Pisconti S, Crispo A, Gebbia V, Maestri A, Galli L, De Giorgi U, Iacovelli R, Buonerba C, Cartenì G, D'Aniello C. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. J Transl Med 2019;17:296. [PMID: 31464635 DOI: 10.1186/s12967-019-2047-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Lasala R, Santoleri F, Romagnoli A, Musicco F, Abrate P, Costantini A. Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma. J Oncol Pharm Pract 2021;:10781552211005518. [PMID: 33847190 DOI: 10.1177/10781552211005518] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]